17 completed, 4 unknown, 3 not yet recruiting, 1 recruiting. 9 Phase 2, 8 Phase 3, 5 Phase 1, 3 Not applicable.
Follow Histoplasmosis: new trials by email Literature Review of Histoplasmosis trials Research Report on Histoplasmosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi Oteseconazole - Coccidioidomycosis, Blastomycosis | Phase 2 | Not yet recruiting | University of Minnesota | 30 | 2026-12-01 | 2026-09-04 |
| Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT) LAmB B, Posaconazole, World Health Organization (WHO)-recommended SOC - Histoplasmosis | Phase 3 | Not yet recruiting | University of Minnesota | 664 | 2026-11-01 | 2026-10-02 |
| Assessment of the Risk of Zoonotic Infections in Prisons in French Guiana Q Fever, Leptospirosis | Not yet recruiting | Centre Hospitalier de Cayenne | 450 | 2026-10-01 | 2026-10-19 | |
| Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS Single high dose of liposomal amphotericin B, L-AmB standard dose - Disseminated Histoplasma Capsulatum Infection, AIDS and Infections | Phase 3 | Recruiting | Federal University of Health Science of Porto Alegre | 279 | 2025-01-16 | 2026-07-27 |
| Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients single dose of L-AmB, 2 doses of L-AmB, 2 weeks of L-AmB - Histoplasmosis, AIDS | Phase 2 | Completed | Alessandro Pasqualotto | 118 | 2020-02-14 | 2025-03-14 |
| Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole SUBA itraconazole, Conventional itraconazole - Invasive Fungal Infections | Phase 2 / Phase 3 | Completed | University of Alabama at Birmingham | 88 | 2018-09-17 | 2023-07-07 |
| Additive Benefit of the Urine LAM Test to Current TB Diagnostics in HIV Positive Adults in Panama City, Panama Urine LAM Ag test - Tuberculosis, HIV | Not applicable | Withdrawn | University of Florida | 2017-11-01 | 2017-12-26 | |
| Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Ibrexafungerp - Invasive Candidiasis, Mucocutaneous Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 233 | 2017-04-01 | 2024-11-20 |
| A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers Lozanoc 50mg, Sporanox 100mg - Superficial Mycoses, Dermatomycoses | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 24 | 2015-07-01 | 2016-03-04 |
| Prevalence of Histoplasmosis in HIV + Patients with a Rapid Diagnostic Test in West Indies HIV | Completed | ANRS, Emerging Infectious Diseases | 727 | 2013-08-01 | 2024-09-03 | |
| Treatment for Presumed Ocular Histoplasmosis aflibercept - Ocular Histoplasmosis | Phase 1 / Phase 2 | Unknown | John Kitchens, MD | 40 | 2013-03-01 | 2014-06-16 |
| Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome ranibizumab - Ocular Histoplasmosis Syndrome | Phase 1 / Phase 2 | Unknown | Retina Associates of Kentucky | 20 | 2009-08-01 | 2009-08-10 |
| A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection ITCZ Oral Solution, ITCZ-IV - Mycoses, Candidiasis | Phase 3 | Completed | Janssen Pharmaceutical K.K. | 55 | 2008-01-01 | 2013-07-25 |
| Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis ranibizumab, verteporfin - Presumed Ocular Histoplasmosis (POHS) | Phase 2 | Unknown | Barnes Retina Institute | 30 | 2007-10-01 | 2009-04-16 |
| Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization Neovascularization, Tuberculosis | Completed | Rafic Hariri University Hospital | 100 | 2007-01-01 | 2008-03-28 | |
| Submacular Surgery Trials (SST) Subfoveal Choroidal Neovascularization Removal - Macular Degeneration, Histoplasmosis | Phase 3 | Completed | National Eye Institute (NEI) | 1999-01-01 | 2009-09-17 | |
| Phase II Pilot Study of Fluconazole for Histoplasmosis, Blastomycosis, and Sporotrichosis fluconazole - Histoplasmosis, Sporotrichosis | Phase 2 | Completed | National Center for Research Resources (NCRR) | 78 | 1991-09-01 | 2006-06-09 |
| Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis itraconazole - Histoplasmosis, Sporotrichosis | Phase 1 / Phase 2 | Completed | National Center for Research Resources (NCRR) | 7 | 1985-03-01 | 2006-06-09 |
| Macular Photocoagulation Study (MPS) Argon Blue-Green Laser Photocoagulation - Choroidal Neovascularization, Macular Degeneration | Phase 3 | Unknown | National Eye Institute (NEI) | 1979-02-01 | 2005-06-24 | |
| Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome Fluconazole - HIV Infections, Histoplasmosis | Not applicable | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 90 | 2021-11-02 |
Showing 20 of 26. Sign in to see all of them.
Acquired Immunodeficiency Syndrome (7) · Blastomycosis (7) · HIV Infections (7) · AIDS-Related Opportunistic Infections (4) · Mycoses (4) · Coccidioidomycosis (3) · Recurrence (3) · Candidiasis (2) · Communicable Diseases (2) · Immune System Diseases (2) · Macular Degeneration (2) · Rare Diseases (2) · Sporotrichosis (2) · Tuberculosis (2)
Bacterial Infections and Mycoses (26) · Infections (25) · Mycoses (22) · Genital Diseases (10) · Immune System Diseases (10) · Urogenital Diseases (10) · Blood-Borne Infections (9) · Communicable Diseases (9) · Immunologic Deficiency Syndromes (9) · Lentivirus Infections (9) · RNA Virus Infections (9) · Retroviridae Infections (9) · Sexually Transmitted Diseases (9) · Sexually Transmitted Diseases, Viral (9) · Virus Diseases (9)
Itraconazole (7) · Fluconazole (2) · Ranibizumab (2) · Amphotericin B (1) · Single Person (1) · Verteporfin (1) · World Health Organization (1) · aflibercept (1) · ibrexafungerp (1) · liposomal amphotericin B (1) · posaconazole (1)
National Institute of Allergy and Infectious Diseases (NIAID) (5) · Janssen, LP (2) · National Center for Research Resources (NCRR) (2) · National Eye Institute (NEI) (2) · University of Minnesota (2) · ANRS, Emerging Infectious Diseases (1) · Alessandro Pasqualotto (1) · Barnes Retina Institute (1) · Boryung Pharmaceutical Co., Ltd (1) · Centre Hospitalier de Cayenne (1) · Federal University of Health Science of Porto Alegre (1) · Janssen Pharmaceutical K.K. (1) · John Kitchens, MD (1) · Rafic Hariri University Hospital (1) · Retina Associates of Kentucky (1)
United States (14) · Brazil (3) · Austria (1) · France (1) · French Guiana (1) · Germany (1) · Japan (1) · Lebanon (1) · Netherlands (1) · Pakistan (1) · Panama (1) · South Africa (1) · South Korea (1) · Spain (1) · Suriname (1)
LJ Wheat (2) · William Dismukes (2) · Ahmad M Mansour, MD (1) · Amy Y Vittor, MD PHD (1) · Andrej Spec, MD (1) · Daiane Dalla Lana, PhD (1) · Daiane F Dalla Lana, PhD (1) · George R Thompson, MD (1) · John Kitchens, MD (1) · John W Kitchens, MD (1) · Judy Aberg (1) · Kevin J. Blinder, MD (1) · Kyun-Seop Bae, M.D., Ph.D. (1) · Luana C Genz Bazana, PhD (1)
PMID 19506188, PMID 17896299, PMID 17923538, PMID 18619571, PMID 19064840, PMID 19427992, PMID 19516120, PMID 19734762, PMID 21320967, PMID 22260085, PMID 22441648, PMID 22687305, PMID 23410808, PMID 30039781, PMID 30630398, PMID 32448209, PMID 32457106, PMID 35584144, PMID 35703611, PMID 37232940, PMID 38440302
2017 (1)